Project Grant R21CA302797
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$422K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award, with Federal Grant ID K08CA290152, was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to The Regents of the University of California, San Francisco. The $282,053 award, effective March 1, 2025 through February 28, 2030, supports research to investigate mechanisms of resistance to immunotherapy in hepatocellular carcinoma (liver cancer). The funded project aims to use single-cell techniques and spatial analysis to examine the role of...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Tulane University is focused on investigating the role of the long non-coding RNA CRNDE in hepatocellular carcinoma (HCC) and its impact on tumor-infiltrating lymphocytes (TILs). The total award amount is $468,139, with a project period from March 15, 2025 to February 28, 2030. The key objectives of this research project are to elucidate the molecular mechanisms by which HCC-derived CRNDE...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...
This $509,448 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research by The Leland Stanford Junior University to investigate antigen-presenting cells in lymph nodes and their role in modulating metastatic tumor progression. The key objectives are to: 1) identify the specific antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development, and 2) assess therapeutic strategies to reprogram...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $634,061 to the University of Maryland, Baltimore to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment (TIME) of liver cancer or hepatocellular carcinoma (HCC) during HIV infection. The 5-year project aims to: 1) Characterize how TAPDC reprogram the HCC TIME in HCC-HIV mouse models and human samples; 2) Define how TAPDC modulate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research aimed at understanding how different forms of cell death, particularly programmed necrosis, can alter the immune response and impact tumor growth. The $568,538 award to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will fund a 5-year study to investigate the role of the cytokine interleukin-1 alpha in mediating immune suppression and promoting...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a Project Grant in the amount of $145,336 to the Sloan-Kettering Institute for Cancer Research located in New York. The grant, titled "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors," will fund research focused on reprogramming hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven...
The National Cancer Institute (NCI) awarded a $149,804 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Pittsburgh. The award will fund research to investigate the impact of the LAG3 protein on CD8+ T cell motility and migration in the context of cancer immunotherapy. The project aims to elucidate the mechanism by which LAG3 restricts T cell motility and determine if reduced motility impacts T cell infiltration into the tumor microenvironment. The...
This Project Grant award of $577,818 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop new effective therapeutic combinations to boost the "abscopal effect" and improve clinical outcomes for patients with advanced cancers treated with radiotherapy. The funded research project will: 1) Dissect the mechanisms by which the immune checkpoint molecule B7-H3 impairs CD8 T cell cytotoxicity, using proximity labeling technologies and mouse models, and...